Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Pain, Postoperative 2Vomiting 1Urinary Incontinence, Stress 1Urinary Incontinence 1Urinary Bladder Neoplasms 1Shoulder Pain 1Psychomotor Agitation 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Ovarian Cysts 1Neuroblastoma 1Neoplasms 1Myofibroma 1Menstruation Disturbances 1Lung Neoplasms 1Liver Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Gynecologic Oncology Patient 1Endometrial Neoplasms 1Cognitive Dysfunction 1Anxiety Disorders 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 56Etoposide 40Filgrastim 37Carboplatin 34Vincristine 30Doxorubicin 30Melphalan 27Topotecan 25Isotretinoin 24Peripheral Blood Stem Cell Transplantation 23Granulocyte Colony-Stimulating Factor 22Cisplatin 21Irinotecan 20sargramostim 18Temozolomide 17humanized 3F8 anti-GD2 monoclonal antibody 15Radiotherapy 153-Iodobenzylguanidine 13Granulocyte-Macrophage Colony-Stimulating Factor 11Busulfan 11dinutuximab 10Interleukin-2 9aldesleukin 8Thiotepa 8Ifosfamide 8etoposide phosphate 7Mesna 7Vorinostat 6Stem Cell Transplantation 6Polymerase Chain Reaction 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroblastoma × Population Groups × Clear all
NCT00072358 2022-05-16

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
291 enrolled 7 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡